Regeneration method for treating heart diseases and vascular system diseases using medicament
A regeneration method using a medicament against heart diseases and vascular system diseases, which comprises administering a polypeptide having granulocyte colony-stimulating factor activity under bone marrow suppressed conditions.
1 . A method for treating heart diseases and vascular system diseases, which comprises administering a polypeptide having granulocyte colony-stimulating factor activity under bone marrow suppressed conditions.
2 . The method according to claim 1 , wherein the polypeptide is a polypeptide comprising the amino acid sequence represented by SEQ ID NO:1.
3 . The method according to claim 1 , wherein the polypeptide is a polypeptide which consists of an amino acid sequence in which at least one amino acid in the amino acid sequence represented by SEQ ID NO:1 is deleted, substituted and/or added, and has granulocyte colony-stimulating factor activity.
4 . The method according to claim 1 , wherein the polypeptide is a polypeptide which consists of an amino acid sequence having a homology of 80% or more with the amino acid sequence represented by SEQ ID NO:1, and has granulocyte colony-stimulating factor activity.
5 . The method according to claim 1 , wherein the polypeptide is a chemically modified polypeptide having granulocyte colony-stimulating factor activity.
6 . The method according to claim 5 , wherein the modified polypeptide is a chemically modified polypeptide with polyalkylene glycol.
7 . The method according to claim 1 , wherein the bone marrow suppressed conditions are bone marrow suppressed conditions which are caused by administration of an antitumor agent having bone marrow suppressive activity.
8 . The method according to claim 7 , wherein the antitumor agent is at least one antitumor agent selected from the group consisting of an alkylating agent, a metabolic antagonist, an antitumor antibiotic, a plant pharmaceutical preparation and a platinum compound.
9 . The method according to claim 7 , wherein the administration of the antitumor agent is administration of an alkylating agent and a metabolic antagonist in combination.
10 . The method according to claim 8 , wherein the alkylating agent is cyclophosphamide.
11 . The method according to claim 9 , wherein the alkylating agent is cyclophosphamide.
12 . The method according to claim 8 , wherein the metabolic antagonist is 5-FU.
13 . The method according to claim 9 , wherein the metabolic antagonist is 5-FU.
14 . The method according to claim 7 , wherein the bone marrow suppressed conditions are bone marrow suppressed conditions in which count of leukocytes in peripheral blood is 90% or less of the count before the administration of the antitumor agent.
15 . The method according to claim 7 , wherein the bone marrow suppressed conditions are bone marrow suppressed conditions in which count of leukocytes in peripheral blood is 75% or less of the count before the administration of the antitumor agent.
16 . The method according to claim 7 , wherein the bone marrow suppressed conditions are bone marrow suppressed conditions in which count of leukocytes in peripheral blood is 60% or less of the count before the administration of the antitumor agent.
17 . The method according to claim 1 , wherein the heart diseases and vascular system diseases are at least one of diseases selected from the group consisting of myocardial infarction, angina pectoris, heart failure, cardiac myopathy and obstructive arteriosclerosis.